Telomir Pharmaceuticals secures $1 million investment, signaling strong investor confidence.

Telomir Pharmaceuticals secured a $1 million investment at $7 per share, marking a 20% increase over its recent stock price. This deal, involving restricted common stock without warrants, signals strong investor confidence. Meanwhile, Scilex Holding Company is forming a joint venture for a potential new oral treatment for obesity and Alzheimer's, currently in phase 2 clinical trials.

December 12, 2024
3 Articles

Further Reading